Moderna’s Melanoma Triumph Faces the Harsh Math of a $60 Billion Valuation

The science is historic. The stock chart is a study in whiplash. Moderna’s first late-stage win for a personalized mRNA cancer therapy has triggered one of the most dramatic re-ratings in recent biotech memory — and the market is already second-guessing itself. Shares of the Cambridge, Massachusetts-based company have more than sextupled from the November […] The post Moderna’s Melanoma Triumph…